CSE Cross Shr Reg S

RNS Number:9484B
Cross Shore Acquisition Corporation
13 August 2007


Cross Shore Acquisition Corporation

13 August 2007

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE
UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH
  AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
              VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

                       Result of Special General Meeting

Cross Shore announces that it has adjourned the Special General Meeting convened
for 10 August 2007 at which, inter alia, Cross Shore Shareholders were to be
asked to vote on a resolution to approve the acquisition of ReSearch 
Pharmaceutical Services Inc. ("Acquisition").

As of 10 August 2007, the company had received sufficient votes against the
Acquisition that the resolution was unlikely to be approved if put to the 
shareholders at the Special General Meeting. In addition, as of 10 August 2007,
approximately 35.4 million warrants had been tendered for exchange pursuant to
the tender offer. This amount reflects an increase of approximately 11.4
million warrants from the amount tendered as of 8 August 2007 but remains
0.2% less than the 95% required to be tendered as a condition to the
Acquisition. Under the terms of the Merger Agreement, this condition is waivable.
The completion of the warrant tender offer also remains conditional on 
completion of the Acquisition and absent completion of the Acquisition, the 
warrants will not convert into shares and will remain as warrants. Pending 
satisfaction of the conditions of the Merger Agreement, either party is entitled
to terminate the Merger Agreement on written notice to the other.

As announced on 3 August 2007, Cross Shore had received expressions of interest 
from third party institutional investors who indicated their interest in acquiring
a significant number of shares and warrants which, if acquired, voted, and 
tendered respectively, may allow the transaction to proceed. Discussions have been
ongoing with one of those institutional investors and the Board of Directors
reasonably believes that it is possible to reach a definitive agreement shortly
to allow the transaction to proceed.

Consequently the Board has decided to extend the adjournment of the Special
General Meeting until a time to be determined in the immediate near future to
allow additional time to enter into such definitive agreement and tabulate
revised proxies.

The adjourned meeting will take place as before at the offices of McDermott,
WIll & Emery, 227 West Monroe Street, Chicago, Illinois 60606. Proxies already 
deposited in respect of the Special General Meeting will remain valid for the 
adjourned meeting, however, if a shareholder wishes to change their vote, they 
should either request and complete a new proxy form or attend the meeting in 
person. A new deadline for the return of proxies will be notified at the same 
time as the date for the adjourned meeting.


ENQUIRIES:

Cross Shore                                 +1 843 597 4760
Dennis Smith

Arbuthnot Securities Limited                +44 207 012 2000
Nominated Adviser
James Steel / Guy Blakeney

This announcement does not constitute, or form part of, an offer or an
invitation to purchase any securities.

This announcement is not for distribution into the United States, Canada, Japan,
Australia, the Republic of Ireland or the Republic of South Africa or any other
jurisdiction where its distribution would constitute a violation of the relevant
laws of such jurisdiction. Neither Cross Shore Shares nor the Cross Shore
Warrants have been registered under the United States Securities Act of 1933, as
amended, or under the applicable securities laws Canada, Japan, Australia, the
Republic of Ireland or the Republic of South Africa. Accordingly (subject to
certain exceptions), neither the Cross Shore Shares nor the Cross Shore Warrants
may, directly or indirectly, be offered or sold within the United States,
Canada, Japan, Australia, the Republic of Ireland or the Republic of South
Africa or to or by any national, resident or citizen of such countries. The
distribution of the Readmission Document in other jurisdictions may be
restricted by law and therefore persons into whose possession the Readmission
Document comes should inform themselves about and observe any such restrictions.
Any failure to comply with these restrictions may constitute a violation of the
securities law of any such jurisdictions.

Arbuthnot Securities Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as nominated adviser and
UK broker to the Company in connection with Re-admission. Its responsibilities
as the Company's nominated adviser under the AIM Rules are owed solely to the
London Stock Exchange and are not owed to the Company or to any Director or
Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their clients or for providing advice in
relation to the contents of this announcement or the Re-admission. No
representation or warranty, express or implied, is made by Arbuthnot Securities
Limited as to the contents of this announcement. The information contained in
this announcement is not intended to inform or be relied upon by any subsequent
purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and
accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation
accept responsibility, individually and collectively, for the information
contained in this announcement and for compliance with the AIM Rules. To the
best of the knowledge and belief of the Directors and Proposed Directors, who
have taken all reasonable care to ensure that such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.

END





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRBCGDIIGBGGRD

Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From May 2024 to Jun 2024

Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From Jun 2023 to Jun 2024